VYSIS die Biotechschmiede die bereits Weltweit agiert. Niederlassung in Bergisch Gladbach. WKN 9121 - 500 Beiträge pro Seite

[Albatossa]

Hallo Leute,

die Niederlassung der Fa. VYSIS in Deutschland war bis Ende
März 1999 in Stuttgart, daraufhin hat sich VYSIS wegen dem
besseren Biotechnischen Umfeld und Perspektiven die Mühe gemacht in den Großraum Köln zu ziehen. Im Moment schreibt die Fa. YSIS immer noch Verluste, die aber verringert wurden. Die Personaldecke ist vergrößert worden, aber es wurde auch best qualifiziertes Personal in Deutschland eingestellt. Mehr weiß ich im Moment nicht. Wer kann mir
da weiter helfen! In Yahoo steht zwar einiges drin, aber man muß die Materie doch auch verstehen!

Gruß Albatossa

[Albatossa]

Hallo Leute,

hier sind die Quartalzahlen von VYSIS.

Wednesday August 9, 8:00 am Eastern Time
Press Release
SOURCE: Vysis, Inc.
Vysis` Mid-Year Results on Target for Breakeven In Fourth Quarter 2000
Second Quarter Net Loss Improves 73 Percent Excluding Non-recurring Items; Clinical Products Revenues Up 26 Percent
DOWNERS GROVE, Ill., Aug. 9 /PRNewswire/ -- Vysis, Inc. (Nasdaq: VYSI - news), a developer and marketer of clinical products providing information for genomic disease management, today reported that continued operational and financial progress in its second quarter and six months ended June 30, 2000, position the company to achieve its breakeven goal in the fourth quarter of 2000. The strong performance was achieved as a result of the successful implementation of the company`s strategies to focus its operations on core product lines and active technology platforms, while reducing expenses through more efficient distribution, appropriately lean staffing and the use of collaborative efforts. Effective marketing programs are contributing to Vysis` growing revenue base with expert testimonials, endorsements from advocacy groups and expanded reimbursement supporting wider exposure of Vysis` product capabilities.

``Growing market adoption of our high-margin clinical products continues to drive our improving performance,`` said John Bishop, president and chief executive officer. ``High-profile research collaborations, pharmacogenomic partnerships like the one recently announced with Genentech Inc., third-party endorsements, and end-user demand are working together to substantially increase awareness of the effectiveness and reliability of our DNA probe product lines. While we`ve had a great run in the first half of 2000, we believe this is just the beginning. The market opportunity is substantial.``

Three Months Results

For the second quarter, sales of genetic testing products for clinical use increased 26 percent over the prior-year quarter. However, research revenues decreased by about 14 percent as a result of the switch from selling direct to selling through distributors in Italy and France at the beginning of the year. Off shore revenue was further eroded by the impact of foreign currency translations. Nevertheless, cost savings related to the transition more than offset the revenue impact, ultimately making European operations more profitable for the company. Total product gross profit margin increased to 72 percent from 58 percent, as a result of the continued growth in higher-margin products.

For the latest three months, net loss was $995,000, or $0.10 per share, a 64 percent improvement over the prior-year quarter. Excluding non-recurring items, net loss improved 73 percent to $745,000, or $0.07 per diluted share, compared with a net loss of $2.8 million, or $0.29 per diluted share, for the second quarter of 1999. Non-recurring items include a gain of $1.3 million resulting from the renewal of a patent license and a patent license option, as well as a charge of approximately $1.5 million related to the expansion of clinical trials for Vysis` FDA-approved PathVysion(TM) assay. These clinical trials are being conducted to obtain additional labeling claims for PathVysion as a method for selecting appropriate candidates for Genentech, Inc.`s Herceptin therapy, a breakthrough treatment for certain patients with breast and other cancers. The net non-recurring charge of $250,000 represents $0.03 per share.

Total revenues for the latest three months were $6.8 million versus $6.5 million last year, reflecting a 5 percent increase. Gross profit was $5.3 million versus $3.8 million for the second quarter of 1999, up 39 percent.

Six Months Results

For the six months, net loss was reduced by 63 percent to $2.3 million, or $0.23 per diluted share, from $6.3 million, or $0.64 per diluted share, last year, despite this year`s one-time net charge previously discussed. A 36 percent increase in clinical product revenues in the first half of 2000 and a 3 percent increase in sales of research reagents were offset by a 67 percent decline in sales of instrument products - a low-margin product line that was divested in July 1999. Consequently, total revenues were essentially unchanged from a year ago.

Product gross margin improved to 73 percent from 60 percent during the six months providing an 8 percent increase in product gross profit dollars. Operating expenses, excluding the non-recurring charge in 2000 and a 1999 restructuring charge, declined by 25 percent in the first half of 2000.

The company ended the second quarter with cash and short-term investments of $7.2 million. In addition, non-recurring receivables from the divestitures in 1999 of the Imaging business and the French distribution subsidiary represent an additional $1.2 million. The company believes its cash resources are sufficient to reach profitability in 2001.

New CFO`s Expertise Supports Growth Objective

In early June, Vysis strengthened its management team with the appointment of John R. Sluis, 54, as senior vice president and chief financial officer. Sluis leads Vysis` corporate finance, treasury, accounting and management information functions. ``We are very pleased to have a leader of John`s caliber joining the company at this important juncture in our growth,`` said Bishop. ``He brings more than 18 years of financial management skills to Vysis, and has an established track record for success. As Vysis continues to expand, John`s expertise in the financial, bio-tech and healthcare arenas will greatly reinforce our efforts.``

Outlook Favorable

``We`re pleased with the results of our programs for controlling expenses, increasing market adoption rates and leveraging our technological capabilities to expand our clinical and research product lines and reduce time to market. We remain on track for submitting our clinical bladder cancer product 510(k) to the FDA in the third quarter, and confirm our financial goal of reaching breakeven in the fourth quarter of this year,`` said Bishop.

Vysis, Inc. of Downers Grove, Ill., is a genomic disease management company that develops, commercializes and markets clinical products providing information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. The company has direct sales operations in the United States and Europe, a marketing partnership in Japan with Fujisawa Pharmaceutical Co., and a worldwide distribution network.

The statements in this press release concerning Vysis` future financial results as well as any other statements that are not historical facts, are forward-looking statements and are subject to risks and uncertainties inherent in the company`s business. These risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements, include: the market acceptance of the company`s clinical products; the extent to which the clinicians or laboratories performing procedures with the company`s products are able to obtain third- party reimbursement; the ability of the company to successfully market and sell its clinical products, other products and equipment; competition; compliance by the company with regulatory requirements and the timely receipt of necessary government approvals; the company`s ability to manufacture products in sufficient quantities; the company`s ability to maintain intellectual property protection for its proprietary products, to defend its existing intellectual property rights from challenges by third parties, and to avoid infringing intellectual property rights of third parties; the success of the company`s collaborators and licensees; and the company`s cost-control efforts. In addition, a detailed discussion of risks and uncertainties may be found in the company`s periodic filings with the Securities and Exchange Commission. Vysis disclaims any intent or obligation to update these forward- looking statements.

To receive Vysis, Inc.`s latest news release and other corporate documents, free of charge via fax, simply dial 1-800-PRO-INFO. Use company ticker VYSI.


VYSIS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)

Three Six
Months Ended Months Ended
6/30/00 6/30/99 6/30/00 6/30/99
Revenues:

FDA/AFSSAPS
clinically
approved genetic
testing products $1,315 $1,042 $2,612 $1,923
Research and other
genetic testing
products 2,573 2,978 5,215 5,055
Genetic instrument
products 649 1,363 941 2,831
Distributed
laboratory products - 282 - 440
Food testing products 724 689 1,443 1,388

Total product
revenue 5,261 6,354 10,211 11,637

License and other
revenue 1,564 118 1,745 279

Total revenues 6,825 6,472 11,956 11,916

Cost of goods sold 1,490 2,639 2,729 4,686

Gross profit 5,335 3,833 9,227 7,230

Operating expenses:

Research &
development 1,712 2,351 3,521 4,828
Acquired clinical
trial data 1,500 - 1,500 -
Selling, general
and administrative 3,250 4,413 6,761 8,834
Restructuring
expense - - - 541

Total operating
expenses 6,462 6,764 11,782 14,203

Loss from operations (1,127) (2,931) (2,555) (6,973)

Gain on sale of
investment - - - 357

Interest income
(expense), net 132 133 241 320

Net loss $(995) $(2,798) $(2,314) $(6,296)

Basic and diluted
net loss per share $(0.10) $(0.29) $(0.23) $(0.64)

Shares used in
computing basic
and diluted net
loss per share 10,079 9,808 10,043 9,800

SOURCE: Vysis, Inc.



August 11, 2000

VYSIS INC (VYSI)
Quarterly Report (SEC form 10-Q)
MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of the Company`s results and financial condition. The discussion should be read in conjunction with the audited consolidated financial statements of the Company and notes thereto, which were included in the Company`s Annual Report on Form 10-K for the year ended December 31, 1999 as well as the financial statements of the Company and notes thereto. This Quarterly Report on Form 10-Q contains certain statements which describe the Company`s beliefs concerning future business conditions and the outlook for the Company based on currently available information. Whenever possible, the Company has identified these "forward-looking" statements (as defined in Section 21E of the Securities Exchange Act of 1934) by words such as "anticipates," "believes," "estimates," "expects," and similar expressions. These forward-looking statements are subject to risks and uncertainties



which could cause the Company`s actual results, performance and achievements to differ materially from those expressed in or implied by these statements. These risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements, include: the market acceptance of the Company`s clinical products; the extent to which the clinicians or laboratories performing procedures with the Company`s products are able to obtain third-party reimbursement; the ability of the Company to successfully market and sell its clinical products, other products and equipment; competition; compliance by the Company with regulatory requirements and the timely receipt of necessary governmental approvals; the Company`s ability to manufacture products in sufficient quantities; the Company`s ability to maintain intellectual property protection for its proprietary products, to defend its existing intellectual property rights from challenges by third parties, and to avoid infringing intellectual property rights of third parties; product liability claims; the success of the Company`s collaborators and licensees; and the Company`s cost control efforts.


OVERVIEW


Vysis, Inc. ("Vysis" or the "Company") is a Genomic Disease Management company that develops, commercializes and markets clinical products that provide information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. Vysis currently markets six U.S. Food and Drug Administration ("FDA") or foreign cleared or approved clinical ("Clinical") products in addition to distributing over 275 Analyte Specific Reagent and research ("ASR/Research") products through its direct sales operations in the United States and Europe and a worldwide distribution network covering 59 countries. The Company`s wholly owned subsidiary, Gene-Trak Systems Industrial Diagnostics Corporation, manufactures and markets food testing kits based on Deoxyribonucleic Acid ("DNA") probes.


RESULTS OF OPERATIONS


Total revenues for the three and six months ended June 30, 2000 were $6.8 million and $12.0 million, respectively, an increase of $0.4 million, or 5%, and flat in comparison to the three and six months ended June 30, 1999. Product revenue for the three months and six months ended June 30, 2000 was $5.3 million and $10.2 million, respectively, a decrease of $1.1 million, or 17%, and $1.4 million, or 12%, as compared to the prior year periods. License and other revenue for the three and six months ended June 30, 2000 was $1.6 million and $1.7 million, respectively, an increase of $1.4 million, or 1225%, and $1.5 million, or 525%, over the comparable prior year periods. The decrease in product revenue for the second quarter and first half of 2000 was primarily attributable to a $0.7 million and $1.9 million reduction in genetic instrument product sales as a result of the Company selling its Quips cytogenetic imaging instrumentation ("Imaging") business during July 1999, which represented nearly all of its genetic instrument business at that time. In addition, distributed laboratory product revenues for the three and six months ended June 30, 2000, decreased by $0.3 million and $0.4 million, respectively, resulting from the Company`s December 1999 sales of its French distribution operations, which included the entire distributed laboratory product line. The second quarter product



revenues of ASR/Research genetic testing products ("Research") also declined $0.4 million, or 14%, as compared to the prior year quarter as a result of flat sales in the U.S. and a decline in European revenue dollars primarily due to the conversion of the Company`s French and Italian sales operations from its own direct sales force in 1999 to more cost effective distribution approach utilizing third party distributors in 2000, which has resulted in a 9% increase in the volume of European Research units sold. For the first half of 2000, Research product revenues increased $0.2 million, or 3%, in comparison to the prior year resulting from a $0.2 million increase in U.S. sales while European revenues were flat, although unit volume increased 10% due to the previously mentioned changes in distribution within France and Italy. For the three and six months ended June 30, 2000, FDA/AFSSAFP approved clinical genetic testing products ("Clinical") revenue increased $0.3 million, or 26%, and $0.7 million, or 36%, respectively, primarily due to the growth in the U.S. adoption rate of the Company`s PathVysion-TM- breast cancer product and AneuVysion-Registered Trademark- prenatal products. The increase in 2000 license and other revenue was primarily due to $1.3 million of license revenue associated with a patent license agreement and an option for a patent license agreement both of which were entered into during the second quarter of 2000.

As a result of the divestiture of the Imaging instrument and distributed laboratory product lines during the second half of last year, cost of goods sold for the three and six months ended June 30, 2000 were $1.5 million and $2.7 million, respectively, representing a decrease of $1.1 million, or 44%, and $2.0 million, or 42%, from the respective prior periods. As a percentage of product revenue, product gross profit increased to 72% and 73% for the three months and six months ended June 30, 2000, respectively, from 58% and 60% in the respective prior year periods due to the Company`s shift in focus to the higher margin Clinical and Research products. Although product revenues have declined during 2000, due to the above divestitures, product gross profit for the three months and six months ended June 30, 2000, has increased by $0.1 million and $0.5 million respectively as compared to the comparable prior year periods.

Research and development expense for the three and six months ended June 30, 2000 were $1.7 million and $3.5 million, respectively, a decrease of $0.6 million, or 27%, and $1.3 million, or 27%, as compared to the prior year periods. The decreases were primarily due to reduced salaries and contract research expenses resulting from the Company`s 1999 restructuring plans which included the elimination of certain positions primarily related to the deferral of research and development on the Company`s Molecular Lawn platform and the divestiture of the Imaging business. During May 2000, the Company entered into a collaborative agreement with Genentech, Inc., the developer of the Herceptin-Registered Trademark- monoclonal antibody treatment for metastatic breast cancer, to extend the use of the Company`s PathVysion-TM- HER-2 breast cancer test kit. In accordance with the agreement, the Company has incurred a charge of $1.5 million for its right to utilize Genentech`s clinical trial data for the Company`s regulatory submission to the U.S. FDA.

Selling, general and administrative expenses for the three and six months ended June 30, 2000 were $3.3 million and $6.8 million, respectively, a decrease of $1.2 million, or 26%, and $2.1 million, or 23%, in comparison to the prior year. The second



quarter and first half reductions were due to a decrease of $1.3 million and $2.5 million, respectively, in selling expense primarily due to the reduction in the number of sales and marketing employees and related costs as a result of divesting the Imaging business and the modification of the European organization to use of distributors in France and Italy and due to the elimination of certain positions partially offset by an increase of $0.1 million and $0.4 million, respectively, in general and administrative expenses primarily due to higher litigation expenses.

During the first quarter of 1999, the Company implemented the first of two restructuring plans in 1999. The Company eliminated 20 positions at various levels throughout the Company during March 1999, which resulted in a $0.5 million restructuring charge for employee severance costs.

The gain on the sale of investments for the six months ended June 30, 1999 was $0.4 million that resulted from the $0.5 million sale of the Company`s investment in Incyte common stock.

Interest income for the three and six months ended June 30, 2000 was $0.1 million and $0.2 million, respectively, representing a slight decline from both of the comparable prior year periods as a result of utilizing the proceeds from the Offering.


INCOME TAXES


Prior to the completion of the Company`s Offering, the results of operations were included in the consolidated income tax returns of BP Amoco; accordingly, the domestic net operating losses through February 10, 1998 have been utilized by BP Amoco in its consolidated income tax returns and are not available to offset the Company`s future taxable income. Subsequent to the Offering, the Company has filed a separate federal income tax returns. As the Company was in a loss position for the six months ended June 30, 1999 and 2000, no federal provision is recorded. For state income taxes, the Company`s results of operations will continue to be included with BP Amoco, due to its 66 percent ownership interest in the Company, in those states where required by state tax law. Under state tax laws in a number of states, including Illinois (the state in which much of the Company`s business is taxed), the Company is required by law to be included in BP Amoco`s unitary state tax returns as long as BP Amoco owns or controls 50 percent or more of the voting equity. For unitary state filings, the tax sharing agreement with BP Amoco requires BP Amoco to pay the Company the incremental tax savings, if any, received by BP Amoco as a result of including the Company`s results of operations in such filings. The agreement also requires the Company to pay BP Amoco the incremental tax liability, if any, incurred by BP Amoco as a result of including the Company`s results of operations in such filings. As a result of BP Amoco`s apportionment factors combined with minimal U.S. based tax losses, the Company has not recorded any state tax benefit for the three and six months ended June 30, 2000. For state income taxes in non-unitary states, the Company has not recorded any benefit as a result of its loss position.



A full valuation allowance has been provided for all deferred tax assets (net of liabilities) at June 30, 2000 as management does not consider realization of such amounts more likely than not.


LIQUIDITY AND CAPITAL RESOURCES


Net cash used in operating activities for the six months ended June 30, 2000 was $1.8 million, a decrease of $6.1 million over the prior year, driven primarily by the $4.0 million reduction in net loss and the $1.9 million reduction in working capital requirements during the first half of 2000 as compared to the prior year.

Net cash used in investing activities for the six months ended June 30, 2000 was $2.7 million, resulting primarily from purchase of short-term investments, net of proceeds. During the prior year, the $5.4 million of net cash flows used in investing activities resulted primarily from the proceeds from the maturities of short-term investments, net of purchase.

Net cash provided by financing activities for the six months ended June 30, 2000 was $0.3 million, a change of $0.6 million from the prior period primarily due to the elimination of debt payments and the increase in proceeds from stock option exercises as well as the contribution of certain services provided by BP Amoco.

At June 30, 2000, the Company had cash, cash equivalents and short-term investments of $7.2 million and an accumulated deficit of $60.8 million. Since its inception, the Company has experienced negative cash flows from operations. In order to preserve the Company`s cash position and to reduce cash used in operating activities, the Company implemented during the first quarter of 1999 a restructuring plan that resulted in the elimination of 20 positions, including open positions, thereby reducing ongoing expenditures by approximately $1.6 million. During the third quarter of 1999, the Company sold its Imaging business to Applied Imaging Corp. ("AI") for total consideration of $3.0 million. Of the $3.0 million in total consideration, the Company has received $1.7 million in cash and 497,368 shares of AI common stock that was valued upon its receipt at $0.5 million. At June 30, 2000 the market value of those securities was $1.1 million. During July 2000 the Company sold these securities for $1.7 million. In addition, AI paid during July 2000 $0.5 million and is further obligated to pay $0.3 million in January 2001. Upon completion of the Imaging business sale, the Company refocused on its core technologies and during the fourth quarter eliminated 37 positions, including open positions as well as certain positions previously associated with the Imaging business, thereby reducing ongoing annual cash expenditures by approximately $2.7 million. At June 30, 2000, the Company has paid substantially all of the severance costs related to the 1999 restructuring plans. In addition the Company sold during December 1999 its French distribution subsidiary for approximately $1.1 million, which has been adjusted for the effect of foreign currency translation. As of June 2000, the Company has received $0.8 million with the remaining balance of $0.3 million due by March 2001.



The Company believes that its current cash and short-term investment position, and the interest to be earned thereon, will be sufficient to fund the Company`s operations through the end of year 2001. The Company`s estimate of the time period for which cash funds will be adequate to fund its operations is a forward looking estimate subject to risks and uncertainty, and actual results may differ materially. The Company`s requirements for additional capital will depend on many factors, including growth in product revenue; payments received under existing and potential collaborative agreements; the availability of government research grant payments; the progress of the Company`s collaborative and independent research and development projects; the costs of preclinical and clinical trials for the Company`s products; the prosecution, defense and enforcement of patent claims and other intellectual property rights; costs of product liability claims; and the development of manufacturing, sales and marketing capabilities. To the extent capital resources, including payments from existing and possible future collaborative agreements and grants, together with the net proceeds of the Offering are insufficient to meet future capital requirements, the Company will have to raise additional funds to continue the development of its technologies. There can be no assurance that such funds will be available on favorable terms, or at all. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities could result in dilution to the Company`s shareholders. If adequate funds are not available, the Company may be required to curtail operations or to obtain funds through entering into collaborative agreements on unattractive terms. The Company`s inability to raise capital as and when needed would have a material adverse effect on the Company`s business, financial condition and results of operations.



ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK


The Company is subject to market risk associated with changes in foreign currency exchange rates and interest rates. The Company`s exchange rate risk is limited to its European operations. The Company`s foreign currency exchange rate risk results primarily from the foreign currency translation of its foreign operations` financial results and from the foreign operations` intercompany purchases of inventory. The majority of the intercompany purchases are to be paid for within standard payment terms of 30 days. Sales throughout the rest of the world are denoted in U.S. dollars. For the three and six months ended June 30, 2000, the foreign exchange rates utilized to translate the Company`s international subsidiaries` local currency financial results into U.S. dollars declined 11% and 12%, respectively, as compared to the prior year periods due to the strengthening of the U.S. dollar against the local currency of these subsidiaries which resulted in a $0.2 million and $0.3 million reduction in net earnings for the three and six months ended June 30, 2000, respectively, in comparison to the prior year periods. The foreign currency translation loss included in shareholders` equity resulting from the translation of the financial statements of the Company`s international subsidiaries into U.S. dollars was flat and increased by $0.1 million for the three and six months ended June 30, 2000, respectively. Interest rate exposure is primarily limited to the $6.7 million of short-term investments owned by the Company. Such securities are debt instruments which generate interest income for the Company on excess cash balances. The Company does not actively



manage the risk of interest rate fluctuations; however, such risk is mitigated by the relatively short term, less than 12 months, nature of these investments.

The Company does not consider the present rate of inflation to have a significant impact on its business.



ITEM 1. LEGAL PROCEEDINGS

As previously disclosed in the Company`s Form 10-Q for the quarter ending March 31, 2000, the Company has been named as the defendant in a declaratory judgment suit filed in the United States District Court in the Southern District of California (San Diego) by Gen-Probe, Inc. The suit seeks a declaration that the Company`s U.S. Patent No. 5,750,338 is invalid and not infringed by certain products for detecting the presence of hepatitis C virus and human immunodeficiency virus in blood specimens. The Company understands that Chiron is currently marketing the products in Australia, France and Germany pursuant to licenses granted by the Company to Gen-Probe and Chiron. The suit also seeks an injunction restraining the Company from interfering with activities by Gen-Probe and its partners regarding these and other products in development; damages and other relief for unfair competition; and a declaration of Gen-Probe`s rights and obligations under its license to the `338 patent. The parties have begun to take discovery and the trial is projected to occur in late 2001. The Company believes Gen-Probe`s claims are without merit and intends to defend its rights vigorously.
Apart from the suit brought by Gen-Probe, the Company has filed an application to reissue the `338 patent with the United States Patent & Trademark Office. The reissue application requests the Patent Office to supplement the claims of the issued patent with new claims of intermediate scope. The Patent Office published notice of the reissue application on July 11, 2000.

Neither loss of the suit filed by Gen-Probe nor an adverse ruling by the Patent Office to the reissue application would limit the sales or marketing of any of the Company`s present or planned products, but could result in the loss of revenue resulting from the licenses granted to Gen-Probe and its partners and other potential licenses granted under the `338 patent. Although there can be no assurance as to the ultimate outcome of the suit, based upon the information available at this time it is the opinion of the Company`s management that the outcome of this suit will not have a material adverse effect on the Company`s business, results of operations and financial condition.


ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

In connection with the Offering (see Note 1 of the Notes to Consolidated Financial Statements for further discussion), the Company received net proceeds of $32.1 million

from the sale of 3,000,000 shares of its Common Stock. From the closing date of the Offering, February 10, 1998, to June 30, 2000, the Company used such net offering proceeds as follows (in millions):


Purchase of short-term investments and cash equivalents ................ $ 7.2 Repayment of note payable-BP Amoco ..................................... 2.0 Acceleration of product development, expansion of sales and marketing capabilities and funding of increased working capital requirements and ongoing operations ............................................... 22.9

------
Total .................................................................. $ 32.1
======

Each of these amounts is a reasonable estimate of the application of the net offering proceeds. This use of proceeds does not represent a material change in the use of proceeds described in the Prospectus for the Offering. Other than the repayment of a note payable to BP Amoco in the amount of $2 million, none of such amounts (with the exception of salaries and directors` fees and working capital advances to affiliates incurred in the ordinary course of business) represented direct or indirect payments to (i) directors or officers of the Company or their associates, (ii) persons owning 10% or more of any class of equity securities of the Company or (iii) affiliates of the Company.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS


On or about May 4, 2000, proxy materials were distributed to all shareholders of record as of the close of business on April 17, 2000. The results of the shareholders` votes were disclosed at the 2000 annual meeting of shareholders (the "Annual Meeting") of the Company which convened on May 31, 2000.

At the Annual Meeting, the following individuals were elected by the votes indicated as directors of the Company until the 2001 Annual Meeting and their successors have been elected and qualified:


NOMINEE FOR WITHHELD
-------------------- --------------------- -------------------

John L. Bishop 9,236,344 4,790
Eileen A. Kamerick 9,237,444 3,690
Kenneth L. Melmon 9,237,444 3,690
Anthony J. Nocchiero 9,131,488 109,646
Walter R. Quanstrom 9,237,444 3,690
Frank J. Sroka 9,131,488 109,646




ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K EXHIBITS

Exhibit 27.1, Financial Data Schedule (included only in the electronic filing of this document).

REPORTS ON FORM 8-K


There were no Form 8-K reports filed during the quarter.



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


VYSIS, INC.



Date: August 9, 2000 By: /s/ JOHN R. SLUIS
----------------------------------------
Name: John R. Sluis
TITLE: SENIOR VICE PRESIDENT, FINANCE
AND CHIEF FINANCIAL OFFICER

[Albatossa]

Hallo Leute,

da Vysis kurz vor dem Breakeven steht, will ich hier mal einen Chart hineinstellen!

Gruß Albatossa

[Albatossa]

Genentech und Vysis gemeinsam gegen Brustkrebs
von Redaktion WO [W:O] 23.05.00 22:05:12
betrifft Aktie: GENENTECH INC.DL-,02 975673
Das Biotechnologieunternehmen Genentech Inc. (NyseNA) und die Biotech-Firma Vysis Inc. (Nasdaq: VYSI) meldeten heute die Unterzeichnung eines Abkommens zur Benutzung des Brustkrebstest-Systems von Vysis. Das Vysis Path Vysion Kit misst die Menge aspezifischer Gene und wird zur Einschätzung von Brustkrebspatienten eingesetzt, für die eine Behandlung mit Herceptin in Frage kommt. Herceptin basiert auf monoklonalen Antikörpern. Dem Path Vysion-System liegt die patentierte FISH (Fluorescence In Situ Hybridiziation) DNA Untersuchungstechnologie zu Grunde.

Genentech und Vysis wollen unter diesem Pakt zusammen weiter an dem Einsatz von Herceptin - für den Gebrauch bei Brustkrebs und anderen Krebsarten - forschen. In naher Zukunft, so hoffen die Unternehmen, kann bei der FDA eine gemeinsame Vorlage für neue Behandlungszulassungen eingereicht werden.

Genentech verliert heute im Zuge des allgemeinen Abwärtstrends 8,99% auf 98 3/4 US-Dollar